NEW YORK, Oct. 25, 2019 /PRNewswire/ -- WeissLaw
LLP is investigating possible breaches of fiduciary duty and
other violations of law by the Board of Fibrocell Science, Inc.
("FCSC" or the "Company") (NASDAQ: FCSC) in connection with the
proposed acquisition of the Company by Castle Creek
Pharmaceuticals, Inc. Under the terms of the acquisition
agreement, FCSC shareholders will receive $3.00 cash for each FCSC share they
own.
If you own FCSC shares and wish to discuss
this investigation or have any questions concerning this notice or
your rights or interests, visit our website:
http://www.weisslawllp.com/fibrocell-science-inc/
Or please contact:
Joshua Rubin, Esq.
WeissLaw LLP
1500 Broadway, 16th Floor
New York, NY 10036
(212) 682-3025
(888) 593-4771
stockinfo@weisslawllp.com
WeissLaw is investigating whether FCSC's Board acted to maximize
shareholder value prior to entering into the acquisition
agreement. Notably, the Company's portfolio includes many
products and therapies at various stages of clinical trials.
Among these is the promising FCX-007, an investigational late-stage
gene therapy candidate for the treatment of recessive dystrophic
epidermolysis bullosa. FCX-007 offers the potential to
address the underlying cause of the disease and is currently in
Phase 3 of clinical trials. If successful, the Company
anticipates filing a Biologics License Application filing in
2021.
Given these facts, WeissLaw is concerned whether the proposed
acquisition undervalues the Company, and whether all material
information related to the proposed acquisition is fully and fairly
disclosed.
WeissLaw LLP has litigated hundreds of stockholder class and
derivative actions for violations of corporate and fiduciary
duties. We have recovered over a billion dollars for
defrauded clients and obtained important corporate governance
relief in many of these cases. If you have information or
would like legal advice concerning possible corporate wrongdoing
(including insider trading, waste of corporate assets, accounting
fraud, or materially misleading information), consumer fraud
(including false advertising, defective products, or other
deceptive business practices), or anti-trust violations, please
email us at stockinfo@weisslawllp.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-weisslaw-llp-investigates-fibrocell-science-inc-300945777.html
SOURCE WeissLaw LLP
